← Back to Clinical Trials
Recruiting NCT04843683

NCT04843683 StereoTactic Ablative RadioTherapy of Cardiac Arrhythmias

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04843683
Status Recruiting
Phase
Sponsor University Health Network, Toronto
Condition Cardiac Arrhythmia
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2021-12-14
Primary Completion 2027-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Stereotactic Ablative Radiotherapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2021-12-14 with a primary completion date of 2027-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a prospective, single-center, phase II trial that will be monitoring the safety and efficacy of using stereotactic ablative radiotherapy (SBRT) to treat patients with a medical condition affecting heart rate and rhythm (refractory arrhythmias) within the University Health Network (Princess Margaret Cancer Centre and Toronto General Hospital). The primary objective will be to prospectively monitor patient cardiac outcomes following SBRT.

Eligibility Criteria

Inclusion Criteria: * Patients with heart rate and rhythm condition (arrhythmia) who have failed standard of care treatment with medication OR at least one prior invasive catheter ablation procedure. * Patients deemed medically fit to receive stereotactic ablative radiotherapy as determined by their Radiation Oncologist. Exclusion Criteria: * Patients who have previously received high dose radiotherapy to the target area and cannot safely receive further treatment OR are unable to receive radiotherapy due to other contraindications.

Contact & Investigator

Central Contact

Benjamin Lok, MD

✉ benjamin.lok@rmp.uhn.ca

📞 416-946-2919

Frequently Asked Questions

Who can join the NCT04843683 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiac Arrhythmia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04843683 currently recruiting?

Yes, NCT04843683 is actively recruiting participants. Contact the research team at benjamin.lok@rmp.uhn.ca for enrollment information.

Where is the NCT04843683 trial being conducted?

This trial is being conducted at Toronto, Canada.

Who is sponsoring the NCT04843683 clinical trial?

NCT04843683 is sponsored by University Health Network, Toronto. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology